The National Animal Supplement Council (NASC) is at the forefront of promoting a groundbreaking study that has shed light on the safety and efficacy of CBD for long-term use in dogs. The study, recently published in the esteemed journal Frontiers in Veterinary Science, has unveiled promising findings that could revolutionize the treatment of various canine conditions.
The research delved into the impact of cannabinoids, including CBD, CBDA, and CBG, on healthy dogs. The study administered a daily dose of 5 milligrams per kilogram of body weight over a 90-day period, followed by a two-week recovery phase. The results were nothing short of remarkable, with the researchers noting that the cannabinoids were well-tolerated in the test subjects.
The findings from this study are particularly significant given the emerging research surrounding cannabis and its potential therapeutic benefits for dogs. From treating anxiety to alleviating skin diseases, CBD has shown promise in improving the quality of life for our furry friends. With these new insights into the safety and tolerability of CBD in dogs, pet owners can now consider this natural remedy as a viable long-term solution for their beloved companions.
The comprehensive nature of this study cannot be understated. In addition to the controlled trial involving healthy beagles, researchers also analyzed more than a decade’s worth of post-market surveillance data from the NASC Adverse Event Reporting Database (NAERS). This meticulous approach provided a holistic view of CBD’s safety profile in dogs and further bolstered the study’s credibility.
NASC President Bill Bookout has expressed his enthusiasm for the study’s outcomes, emphasizing that the cannabis components examined were deemed safe for long-term use in healthy dogs at the studied dosage. The rigorous methodology employed in this research sets a new standard for safety assessments in veterinary medicine and underscores the importance of post-market surveillance in ensuring product integrity.
This study adds to a growing body of scientific literature supporting the benefits of cannabis for canines. Recent case studies have highlighted CBD’s potential as an alternative treatment option for common skin diseases and stress-related conditions in dogs. From reducing seizures to improving arthritis symptoms, CBD has emerged as a multifaceted therapeutic agent with far-reaching implications for veterinary care.
While these findings are undoubtedly promising, regulatory bodies such as the Food and Drug Administration (FDA) have raised concerns about the lack of data surrounding CBD products for animals. Warning letters issued to businesses marketing such products underscore the need for further research to establish safe dosage levels and potential residues in animal-derived foods.
Despite these regulatory challenges, ongoing studies continue to explore the therapeutic potential of CBD across different animal species. From cows fed hempseed cake to horses benefiting from CBD’s calming effects, researchers are uncovering new ways to harness this natural compound for veterinary applications.
As we navigate this evolving landscape of cannabis-based therapies for animals, it is essential to prioritize evidence-based research and stringent safety assessments. The NASC-funded study represents a significant step forward in our understanding of CBD’s safety and efficacy in dogs—a milestone that could pave the way for more targeted treatments and improved outcomes in veterinary medicine.
